Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective
Sign Up to like & getrecommendations! Published in 2025 at "Targeted Oncology"
DOI: 10.1007/s11523-025-01150-8
Abstract: Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, has been established as an effective androgen deprivation therapy (ADT) for advanced prostate cancer, offering advantages over traditional GnRH agonists. The combination of relugolix with androgen receptor… read more here.
Keywords: receptor; receptor pathway; prostate cancer; androgen receptor ... See more keywords
Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
Sign Up to like & getrecommendations! Published in 2019 at "Fertility and sterility"
DOI: 10.1016/j.fertnstert.2019.07.013
Abstract: OBJECTIVE To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid-associated pain. DESIGN Phase 3, multicenter, randomized, double-blind, placebo-controlled study. SETTING Centers. PATIENT(S) Premenopausal Japanese women… read more here.
Keywords: relugolix; treatment; study; oral gonadotropin ... See more keywords
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
Sign Up to like & getrecommendations! Published in 2020 at "Fertility and sterility"
DOI: 10.1016/j.fertnstert.2020.07.055
Abstract: OBJECTIVE To evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain. DESIGN Phase 2, multicenter, randomized, double-blind, placebo-controlled… read more here.
Keywords: dose response; response manner; relugolix; associated pain ... See more keywords
Relugolix Combination Therapy Improves Hemoglobin Levels in Anemic Women with Uterine Fibroids: Results from the Liberty Phase 3 Program
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Minimally Invasive Gynecology"
DOI: 10.1016/j.jmig.2020.08.315
Abstract: Study Objective To evaluate the effect of Relugolix combination therapy (Rel-CT) on hemoglobin in women with uterine fibroids (UF) and anemia. Design LIBERTY 1 and 2 are phase 3, multinational, randomized, double-blind, placebo-controlled studies. Setting… read more here.
Keywords: relugolix; volume; relugolix combination; uterine fibroids ... See more keywords
Presurgical treatment of uterine myomas with the GnRH-antagonist relugolix in combination therapy: an observational study
Sign Up to like & getrecommendations! Published in 2024 at "Scientific Reports"
DOI: 10.1038/s41598-024-73151-y
Abstract: To evaluate if a preoperative medical treatment with the GnRH-antagonist relugolix in combination therapy in a series of patients with abnormal uterine bleeding associated with uterine myomas may correct the anemia before scheduled surgery for… read more here.
Keywords: combination therapy; relugolix combination; gnrh antagonist; uterine myomas ... See more keywords
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
Sign Up to like & getrecommendations! Published in 2021 at "BMC Women's Health"
DOI: 10.1186/s12905-021-01475-2
Abstract: Background Uterine leiomyomas are the most common neoplasm affecting women and frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone (GnRH) receptor antagonists provide fast symptom relief and show promise as a medical (non-surgical) treatment… read more here.
Keywords: uterine leiomyomas; relugolix; trial; treatment ... See more keywords
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.301
Abstract: 301 Background: Relugolix, an oral gonadotropin releasing hormone (GnRH) antagonist, has superior testosterone suppression and may lower cardiovascular (CV) toxicity compared with more commonly used injectable GnRH agonists, such as leuprolide. The Relugolix Versus Leuprolide… read more here.
Keywords: treatment; prostate; relugolix versus; trial ... See more keywords
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.4_suppl.85
Abstract: 85 Background: Relugolix is the first oral GNRH antagonist approved by the FDA in 2021 for the treatment of advanced prostate cancer (PCa). Approval was based on HERO study, which showed a rapid and sustained… read more here.
Keywords: oncology; combination; real world; tolerability ... See more keywords
Venous Thromboembolism Risk Associated with Relugolix-Estradiol-Norethisterone Acetate Combination Therapy
Sign Up to like & getrecommendations! Published in 2025 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvaf190
Abstract: Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol (E2) and norethisterone… read more here.
Keywords: estradiol norethisterone; vte risk; risk; risk associated ... See more keywords
The impact of neoadjuvant relugolix on multi-dimensional patient-reported fatigue
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1412786
Abstract: Introduction Androgen deprivation therapy has been shown to improve cancer control when combined with radiotherapy. Relugolix is an oral GnRH receptor antagonist that achieves rapid profound testosterone suppression, which may increase the perception and/or impact… read more here.
Keywords: clinically significant; fatigue; neoadjuvant relugolix; impact neoadjuvant ... See more keywords
An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.874973
Abstract: Relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, has been well studied in the treatment of endometriosis symptomatic. It is mainly metabolized by the CYP3A subfamily of P450 enzymes, while minorly metabolized by CYP2C8. Daidzein in… read more here.
Keywords: efficient uplc; day; daidzein; relugolix ... See more keywords